# US 2023/0068672 A1 · Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with msh3 activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068672 A1
- Document ID: US20230068672A1
- Status: Published application
- Kind: A1
- Application number: 17/842,478
- Filed: 2022-06-16
- Published: 2023-03-02
- Earliest claimed: 2020-06-03
- Assignees: Triplet Therapeutics, Inc.
- Applicants: Triplet Therapeutics, Inc.
- Inventors: Nessan Anthony Bermingham; Brian R. Bettencourt; Pei Ge
- Web page: https://patentgrep.com/patent/US20230068672A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/335: Modified T or U
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/35: based on a specific dosage / administration regimen
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure features useful compositions and methods to treat nucleotide repeat expansion disorders, e.g., in a subject in need thereof. In some aspects, the compositions and methods described herein are useful in the treatment of disorders associated with MSH3 activity.

## Claims

### Claim at position 1

-12. (canceled)

### Claim 13

A single-stranded oligonucleotide of 15-30 linked nucleotides in length, wherein the oligonucleotide, or a portion thereof, is at least 95% complementary to at least 15 contiguous nucleobases at positions 2685-2714 of SEQ ID NO: 614, or a pharmaceutically acceptable salt thereof.

### Claim at position 3

-16. (canceled)

### Claim 17 (depends on 13)

The oligonucleotide of claim 13, wherein the oligonucleotide, or a portion thereof is complementary to 17-23 contiguous nucleobases at positions 2685-2714 of SEQ ID NO: 614, or a pharmaceutically acceptable salt thereof.

### Claim at position 5

-26. (canceled)

### Claim 27 (depends on 13)

The oligonucleotide of claim 13, wherein the oligonucleotide comprises:
(a) a DNA core sequence comprising linked deoxyribonucleosides;
(b) a 5′ flanking sequence comprising linked nucleosides; and
(c) a 3′ flanking sequence comprising linked nucleosides;
wherein the DNA core comprises a region of at least 10 contiguous nucleobases positioned between the 5′ flanking sequence and the 3′ flanking sequence; wherein the 5′ flanking sequence and the 3′ flanking sequence each comprises at least two linked nucleosides; and wherein at least one nucleoside of each flanking sequence comprises an alternative nucleoside, or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 13)

The oligonucleotide of claim 13, wherein the oligonucleotide comprises at least one alternative internucleoside linkage, or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 28)

The oligonucleotide of claim 28, wherein the at least one alternative internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim at position 9

-31. (canceled)

### Claim 32 (depends on 13)

The oligonucleotide of claim 13, wherein the oligonucleotide comprises at least one alternative nucleobase, or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 32)

The oligonucleotide of claim 32, wherein the alternative nucleobase is 5′-methylcytosine, pseudouridine, or 5-methoxyuridine.

### Claim 34 (depends on 13)

The oligonucleotide of claim 13, wherein the oligonucleotide comprises at least one alternative sugar moiety, or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 34)

The oligonucleotide of claim 34, wherein the alternative sugar moiety is 2′-OMe or a bicyclic nucleic acid.

### Claim at position 14

-112. (canceled)

### Claim 113 (depends on 13)

The oligonucleotide claim 13, wherein the oligonucleotide is selected from the group consisting of Antisense Oligo Nos. 289-384 of Table 3, or a pharmaceutically acceptable salt thereof.

### Claim at position 16

-132. (canceled)

### Claim 133 (depends on 13)

The oligonucleotide of claim 13, wherein the oligonucleotide is Antisense Oligo No. 289 of Table 3, or a pharmaceutically acceptable salt thereof.

### Claim at position 18

-159. (canceled)

### Claim 160 (depends on 13)

A pharmaceutical composition comprising one or more of the oligonucleotides, or pharmaceutically acceptable salts thereof, of claim 13 and a pharmaceutically acceptable carrier or excipient.

### Claim at position 20

-162. (canceled)

### Claim 163 (depends on 13)

A method of treating, preventing, or delaying the progression a nucleotide repeat expansion disorder in a subject in need thereof, the method comprising administering to the subject one or more of the oligonucleotides, or pharmaceutically acceptable salts thereof, of claim 13.

### Claim at position 22

-167. (canceled)

### Claim 168 (depends on 163)

The method of claim 163, wherein the subject is a human.

### Claim 169

(canceled)

### Claim 170 (depends on 163)

The method of claim 163, wherein the subject is identified as having a nucleotide repeat expansion disorder.

### Claim 171 (depends on 170)

The method of claim 170, wherein the nucleotide repeat expansion disorder is spinocerebellar ataxia type 36 or frontotemporal dementia.

### Claim 172 (depends on 170)

The method of claim 170, wherein the nucleotide repeat expansion disorder is a trinucleotide repeat expansion disorder.

### Claim 173 (depends on 172)

The method of claim 172, wherein the trinucleotide repeat expansion disorder is a polyglutamine disease.

### Claim 174 (depends on 173)

The method of claim 173, wherein the polyglutamine disease is selected from the group consisting of dentatorubropallidoluysian atrophy, Huntington's disease, spinal and bulbar muscular atrophy, spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 6, spinocerebellar ataxia type 7, spinocerebellar ataxia type 17, and Huntington's disease-like 2.

### Claim 175 (depends on 172)

The method of claim 172, wherein the trinucleotide repeat expansion disorder is a non-polyglutamine disease.

### Claim 176 (depends on 175)

The method of claim 175, wherein the non-polyglutamine disease is selected from the group consisting of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, fragile XE mental retardation, Friedreich's ataxia, myotonic dystrophy type 1, spinocerebellar ataxia type 8, spinocerebellar ataxia type 12, oculopharyngeal muscular dystrophy, Fragile X-associated premature ovarian failure, FRA2A syndrome, FRA7A syndrome, and early infantile epileptic encephalopathy.

### Claim at position 32

-180. (canceled)

### Claim 181 (depends on 174)

The method of claim 174, wherein the trinucleotide repeat expansion disorder is Huntington's disease.

### Claim at position 34

-183. (canceled)

### Claim 184 (depends on 170)

The method of claim 170, wherein the oligonucleotide, pharmaceutical composition, or composition is administered intrathecally, intraventricularly, intracerebroventricularly, intraocularly, subcutaneously, intravenously, intra cisterna magnally, intramuscularly, or orally.

### Claim at position 36

-205. (canceled)
